Abstract
Capillary electrochromatography (CEC) has been used to separate pharmaceuticals from their related impurities; however, this has not been fully explored to date within the pharmaceutical industry. Generally capillary electrophoresis is used in either free-flow mode or in combination with micellar electrokinetic mode to complement the results obtained from the traditional method of high-performance liquid chromatography (HPLC). This paper explores the various separation modes now at hand in pharmaceutical laboratories using a developmental Lilly compound LY300164 and its process impurities. Possible benefits and concerns for each of the separation modes are discussed using the same sample and impurities to generate the results. Regulatory bodies prefer that purity assays for pharmaceuticals be complemented with another technique. This is to guarantee that no other hypothetical impurities which could potentially be present are seen in another technique. Traditionally, HPLC has been complemented with the use of thin-layer chromatography. This paper suggests that CEC can be used as a alternative purity assay for pharmaceuticals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
